Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Lotus Eye Hospital and Institute Gelecekteki Büyüme
Future kriter kontrolleri 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Lotus Eye Hospital and Institute.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
n/a
EPS büyüme oranı
Healthcare kazanç büyümesi | 26.2% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | None |
Son güncelleme | n/a |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking
Aug 21Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Lotus Eye Hospital and Institute yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.
SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
6/30/2024 | 485 | 22 | N/A | N/A | N/A |
3/31/2024 | 482 | 29 | 0 | 57 | N/A |
12/31/2023 | 485 | 35 | N/A | N/A | N/A |
9/30/2023 | 486 | 40 | -1 | 57 | N/A |
6/30/2023 | 477 | 41 | N/A | N/A | N/A |
3/31/2023 | 470 | 41 | 13 | 44 | N/A |
12/31/2022 | 464 | 40 | N/A | N/A | N/A |
9/30/2022 | 459 | 42 | 13 | 69 | N/A |
6/30/2022 | 449 | 46 | N/A | N/A | N/A |
3/31/2022 | 389 | 30 | -3 | 44 | N/A |
12/31/2021 | 389 | 36 | N/A | N/A | N/A |
9/30/2021 | 372 | 32 | 37 | 49 | N/A |
6/30/2021 | 335 | 20 | N/A | N/A | N/A |
3/31/2021 | 324 | 16 | 23 | 27 | N/A |
12/31/2020 | 300 | -5 | N/A | N/A | N/A |
9/30/2020 | 301 | -14 | 8 | 26 | N/A |
6/30/2020 | 335 | -6 | N/A | N/A | N/A |
3/31/2020 | 406 | 11 | 26 | 50 | N/A |
12/31/2019 | 420 | 21 | N/A | N/A | N/A |
9/30/2019 | 415 | 20 | N/A | N/A | N/A |
6/30/2019 | 401 | 11 | N/A | N/A | N/A |
3/31/2019 | 384 | 7 | -5 | 42 | N/A |
12/31/2018 | 382 | 7 | N/A | N/A | N/A |
9/30/2018 | 381 | 9 | N/A | N/A | N/A |
6/30/2018 | 384 | 14 | N/A | N/A | N/A |
3/31/2018 | 380 | 17 | N/A | 58 | N/A |
12/31/2017 | 373 | 8 | N/A | N/A | N/A |
9/30/2017 | 359 | 4 | N/A | N/A | N/A |
6/30/2017 | 350 | 6 | N/A | N/A | N/A |
3/31/2017 | 340 | 4 | N/A | 30 | N/A |
12/31/2016 | 330 | 7 | N/A | N/A | N/A |
9/30/2016 | 324 | 7 | N/A | N/A | N/A |
6/30/2016 | 314 | 0 | N/A | N/A | N/A |
3/31/2016 | 311 | 1 | N/A | 34 | N/A |
12/31/2015 | 311 | -5 | N/A | N/A | N/A |
9/30/2015 | 315 | -6 | N/A | N/A | N/A |
6/30/2015 | 308 | -14 | N/A | N/A | N/A |
3/31/2015 | 302 | -20 | N/A | 24 | N/A |
12/31/2014 | 298 | -12 | N/A | N/A | N/A |
9/30/2014 | 290 | -9 | N/A | N/A | N/A |
6/30/2014 | 289 | 1 | N/A | N/A | N/A |
3/31/2014 | 288 | 0 | N/A | 44 | N/A |
12/31/2013 | 287 | 4 | N/A | N/A | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if LOTUSEYE's forecast earnings growth is above the savings rate (6.7%).
Kazançlar ve Piyasa: Insufficient data to determine if LOTUSEYE's earnings are forecast to grow faster than the Indian market
Yüksek Büyüme Kazançları: Insufficient data to determine if LOTUSEYE's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than the Indian market.
Yüksek Büyüme Geliri: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if LOTUSEYE's Return on Equity is forecast to be high in 3 years time